FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled July 1, 2026

Carton Label recall — The Harvard Drug Group LLC

Hazard: Subpotent Drug

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0609-2026
Brand
The Harvard Drug Group
Classification
Class II
Units affected
790 Cartons.
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (2 x 10), Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, in 46268, NDC 0904-7282-10. Blister Label: Methylergonovine Maleate Tablets, 0.2 mg, USP, One Tablet, Major Pharm/Indianapolis, IN 46268, NDC 0904-7282-10.

Affected products

Companies & origin

Recalling firm location
Dublin, OH, United States
Firm address
7000 Cardinal Pl, N/A, 43017-1091

Identifying details (verbatim from the notice)

Product codes / lots
Lots: N02327, expires: 09/2026; N02740, expires: 12/2026; N03069, expires: 08/2027.
Distribution
U.S. Nationwide.
Firm notified the public via
Letter
FDA event ID
99240
Recall initiated
June 16, 2026
FDA classified
June 22, 2026
FDA report date
July 1, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page